Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome

Case Reports in Hematology
Saba F AliHooman H Rashidi

Abstract

Most myelodysplastic syndromes (MDS) present with loss or gain of chromosomal material and less commonly show translocations as a sole abnormality. In addition, certain translocations are more commonly seen in MDS than others, but to our knowledge, the presence of t(6;15) has not been reported in MDS, specifically therapy-related MDS (t-MDS) cases. Patients with t-MDS, a group of heterogeneous stem cell related disorders resulting as a latent complication of cytotoxic and/or radiation therapy, generally tend to have a poorer prognosis than de novo MDS. We present a unique case of a patient who initially presented with acute myeloid leukemia (AML) with a normal karyotype and FLT3-ITD and NPM1 mutations. The patient was successfully treated with chemotherapy and an autologous bone marrow transplant but subsequently developed a new FLT3-ITD negative t-MDS with a unique translocation, t(6;15)(q12;q15), three years after transplant. To our knowledge, this unique sole translocation has never been reported in MDS or t-MDS and given her successful response to treatment and remission, presence of this translocation may have some prognostic value.

References

Jul 1, 1988·Journal of Medical Genetics·A Schinzel
Jun 4, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D CosoR Bouabdallah
Sep 22, 2001·Cancer Genetics and Cytogenetics·C V FernandezP H Sorensen
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James O ArmitageStewart Kroll
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang KernClaudia Schoch
Jan 11, 2007·American Journal of Clinical Pathology·Zeba N SinghJames W Vardiman
Jun 2, 2007·British Journal of Haematology·Claire Seedhouse, Nigel Russell
Aug 12, 2008·Seminars in Oncology·Lucy A Godley, Richard A Larson
Jul 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher T CummingsDouglas K Graham
Aug 20, 2014·Annals of Hematology·Eduard SchulzHeinz Sill
Feb 11, 2015·Best Practice & Research. Clinical Haematology·Brian A Jonas, Peter L Greenberg

❮ Previous
Next ❯

Citations

Jul 31, 2020·Medicina·Yuliya Andreevna VeryaskinaIgor Fyodorovich Zhimulev

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies
PCR
electrophoresis
MDS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.